PACT Pharma is working on a solution that targets a protein on the surface of the cancer cell. This seems at odds with either Dr Rosenberg's or Dr. Cooper's point that solid cancers must be attacked based off of a protein inside the cell rather than on the surface. This is why CAR-Ts won't work for solid cancers as they target a surface protein.
PACT Pharma describes its TCR therapy here: http://www.pactpharma.com/wp-content/uploads/2019/03/AACR-PACT-Poster-Sennino-2019-03-29.pdf
as "a precision genome engineered to express one autologous T cell receptor targeting a
neoepitope presented exclusively on the surface of the patient’s tumor cells (neoTCR)"